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TTR-mediated oligomer clusteringAlthough human transthyretin (TTR) is associated with systemic amyloidoses, an anti-amyloidogenic effect that
prevents Aβ ﬁbril formation in vitro and in animalmodels has been observed. Herewe studied the ability of three
different types of TTR, namely human tetramers (hTTR),mouse tetramers (muTTR) and an engineeredmonomer
of the human protein (M-TTR), to suppress the toxicity of oligomers formed by two different amyloidogenic pep-
tides/proteins (HypF-N and Aβ42). muTTR is themost stable homotetramer, hTTR can dissociate into partially un-
folded monomers, whereas M-TTR maintains a monomeric state. Preformed toxic HypF-N and Aβ42 oligomers
were incubated in the presence of each TTR then added to cell culture media. hTTR, and to a greater extent M-
TTR, were found to protect human neuroblastoma cells and rat primary neurons against oligomer-induced tox-
icity, whereasmuTTRhad noprotective effect. The thioﬂavin T assay and site-directed labeling experiments using
pyrene ruled out disaggregation and structural reorganizationwithin the discrete oligomers following incubation
with TTRs, while confocal microscopy, SDS-PAGE, and intrinsic ﬂuorescencemeasurements indicated tight bind-
ing between oligomers and hTTR, particularly M-TTR.Moreover, atomic force microscopy (AFM), light scattering
and turbidimetry analyses indicated that larger assemblies of oligomers are formed in the presence ofM-TTR and,
to a lesser extent, with hTTR. Overall, the data suggest a generic capacity of TTR to efﬁciently neutralize the tox-
icity of oligomers formed bymisfolded proteins and reveal that such neutralization occurs through amechanism
of TTR-mediated assembly of protein oligomers into larger species, with an efﬁciency that correlates inversely
with TTR tetramer stability.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Transthyretin (TTR) is a homotetrameric protein with a total molecu-
lar mass of 55 kDa that was originally thought to be synthesized only in
the liver, choroid plexus of the brain, and retina [1,2]. Further studies
have demonstrated signiﬁcant and perhaps physiologically importanteta peptide; BSA, bovine serum
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ights reserved.synthesis in the pancreas, kidneys, Schwann cells and neurons [3–7]. In
the plasma TTR transports thyroxine (T4) and the retinol binding protein
charged with retinol (RBP), whereas in the cerebrospinal ﬂuid (CSF) TTR
is the primary transporter of T4 [8,9]. TTR is also one of 30 human pro-
teins associatedwith systemic amyloidoses, a group of disorders original-
ly deﬁned pathologically by the formation and aggregation of misfolded
proteins which result in extracellular congophilic deposits that impair
organ function [10]. Amyloidotic deposition of wild-type TTR occurs in
the heart of 10–25% of humans older than 80 years, resulting in senile
systemic amyloidosis (SSA), often leading to congestive heart failure
[11,12]. TTRﬁbrillogenesis is accelerated by the presence of any of the ap-
proximately 100 different amyloidogenic mutations responsible for
early-onset TTR amyloidoses (http://www.amyloidosismutations.com/
mut-attr.php). These mutations are responsible for the reduced thermo-
dynamic and/or kinetic stability of native tetrameric TTR [13], leading to
the autosomal dominant disorders familial amyloid neuropathy (FAP), fa-
milial amyloid cardiomyopathy (FAC) and the rare leptomeningeal amy-
loidosis [14,15].
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that prevents ﬁbril formation of the amyloid β (Aβ) peptide associated
with Alzheimer's disease (AD) has been proposed for TTR. In 1993 it
was found that in vitro amyloid ﬁbril formation by Aβ40 was inhibited
by human CSF [16]. Although clusterin and apolipoprotein E were also
present in the CSF, the responsible protein was later found to be TTR,
through the formation of stable complexes between Aβ40 and TTR [17].
In the same study it was also found that puriﬁed human TTR inhibited
Aβ28ﬁbril formation in vitro. Overexpression of human TTR in transgenic
Caenorhabditis elegans expressing human Aβ42 led to the reduction of
ThS-positive Aβ deposits in the muscle cells of the nematodes [18]. Sim-
ilarly, overexpression of WT human TTR in transgenic AD model mice
carrying amutant of the human Aβ gene led to a reduction in the Aβ de-
posits in the brains of thesemice,while silencing the endogenousmurine
TTR genes accelerated disease progression in some mouse models
[19,20]. Importantly, the reduction of amyloid deposition by overexpres-
sion of human TTR prevented the loss of spatial memory and learning
usually seen in the AD mice [20].
Analyses of the in vitro interaction between human TTR and Aβ, using
predominantly solid phase assay systems, have shown that TTR binds to
all forms of Aβ: monomers, oligomers and ﬁbrils [20–23]. The binding is
highly dependent on the quaternary structure of TTR, with monomeric
TTR binding Aβ with higher afﬁnity than tetrameric TTR [23]. Moreover,
the binding occurs with higher afﬁnity for Aβ oligomers, aggregates and
ﬁbrilswith respect toAβmonomers [20,21,23,24]. In addition to inhibiting
Aβ ﬁbril formation, TTR was also shown to bind to preformed Aβ oligo-
mers and ﬁbrils and reduce their toxicity to murine primary neurons
and human neuroblastoma SH-SY5Y cells [25].
In the light of the results obtained so far, one can hypothesize that
TTR may act as an endogenous detoxiﬁer of protein oligomers with po-
tential pathological effects, in addition to inhibiting amyloid ﬁbril for-
mation [9]. However, it is not clear if such an effect is speciﬁc for Aβ
oligomers or more generic, interacting with a variety of misfolded pro-
tein oligomers. In addition, previous data do not offer any insight into
the mechanism by which TTR inhibits oligomer toxicity and on the
TTR form responsible for such an effect. We have previously shown
that the in vitro cytotoxicity of protein oligomers formed by Aβ, IAPP
and HypF-N can be suppressed by molecular chaperones, with three
of the ﬁve tested chaperones being extracellular [26]. In particular, it
was shown that the chaperones inhibit the toxicity of the oligomers
by binding to themandpromoting their clustering into large aggregates,
in the absence of any disaggregation or structural reorganizationwithin
the individual oligomers.
In this study we have examined the ability of three types of TTR
having different tetramer stability, i.e., human TTR (hTTR), mouse TTR
(muTTR) and an engineered monomer of human TTR carrying the
F87M and L110M mutations (making it unable to form tetramers
under our experimental conditions) (M-TTR), to suppress the in vitro
toxicity of oligomers formed by two different peptides/proteins, i.e.,
Aβ42 and HypF-N. muTTR is the most stable homotetramer that does
not dissociate into partially unfolded monomers under physiologic con-
ditions on any timescale [8]; hTTR forms stable tetramers but dissociates
to monomers at a ﬁnite rate depending on environmental condi-
tions [27], whereas M-TTR exists as a stable monomer [23,28,29]. As
recently shown in experiments using these three conformers as well as
a series of mutant human TTR tetramers of varying stability, the capacity
of TTR to inhibit Aβ ﬁbril formation is generally inversely related to
tetramer stability [Li et al., submitted]. We now show that the three
types of TTR display different protective effects against oligomer-
induced cytotoxicity.Wehave gainedmolecular insight into the underly-
ing mechanism by which suppression of oligomer cytotoxicity occurs
in vitro, showing that the degree of TTR-mediated protection is greatest
for themonomericM-TTR and least for themost stablemurine tetramer.
Binding to the HypF-N and Aβ42 oligomers appears to promote their
clustering into larger aggregates in the absence of any structural
reorganization.2. Materials and methods
2.1. Materials
All reagentswere of analytical grade or of the highest purity available.
Aβ42, bovine serum albumin (BSA), fetal bovine serum (FBS), hen egg
white lysozyme (HEWL), pluronic acid F-127, staurosporine and other
chemicals were from Sigma-Aldrich (Milan, Italy), unless otherwise stat-
ed. Fluo3-AM, calcein-AM and CM-H2DCFDA (Life Technologies, CA,
USA) were prepared as stock solutions in dimethylsulfoxide (DMSO),
dried under nitrogen and stored in light-protected vessels at −20 °C
until use. Neurobasal medium and B-27 were from Gibco (Life Technol-
ogies, CA, USA).
2.2. Cell cultures
Human SH-SY5Y neuroblastoma cells (ATCCMicrobiology,Manassas,
VA)were cultured in DMEM, F-12 Hamwith 25 mMHEPES and NaHCO3
(1:1) and supplemented with 10% FBS, 1.0 mM glutamine and antibi-
otics. Cell culturesweremaintained in a 5.0%CO2humidiﬁed atmosphere
at 37 °C and grown until they reached 80% conﬂuence for amaximum of
20 passages.
2.3. Formation of protein oligomers
HypF-Nwas expressed, puriﬁed, and converted into toxic aggregates
as previously reported [30]. Aβ42 oligomers were produced as reported
[31] and resuspended in the cell culture medium at a concentration of
12 μM. HypF-N oligomers were centrifuged at 16,100 rcf for 10 min,
dried under N2 and resuspended in cell culture media in the absence
of cells (for cell biology tests) or in 20 mM potassium phosphate buffer
at pH 7.0 (for biophysical/biochemical analysis). As reported, no signif-
icant dissolution of the HypF-N oligomers or change in morphology/
structure could be detected after this procedure [30]. Native proteins
were diluted to a ﬁnal concentration of 12 μM into the same media.
Oligomers were then incubated in the appropriate media for 1 h at
37 °C while shaking, in the absence or presence of each TTR, and then
added to cultured cells or subjected to biophysical/biochemical analysis.
The protein:TTR molar ratio was 10:1, unless stated otherwise (hTTR,
muTTR and M-TTR are considered as tetramers).
2.4. Preparation of TTRs
hTTR, muTTR and M-TTR were prepared and puriﬁed in an Escherichia
coli expression systemas described elsewhere [28,32,33]. The three protein
variants were puriﬁed by gel ﬁltration on a Superdex 75 column
(Amersham Biosciences, Inc.) in 10 mM phosphate buffer, 100 mM KCl,
1 mM EDTA pH 7.6 before each experiment to ensure that no aggregates
were present in the startingmaterial. Liquid chromatography–electrospray
ionizationmass spectrometrywas used to conﬁrm themolecularweight of
the proteins.
2.5. MTT reduction assay
The effect of protein oligomers on cell viability was assessed using SH-
SY5Y cells and primary neurons from rat brains seeded in 96-well plates,
and using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay as described [34]. Preformed oligomers of HypF-N and
Aβ42 (12 μMmonomer concentration) were incubated for 1 h in the ab-
sence or presence of hTTR,muTTR,M-TTR, haptoglobin,α2-macroglobulin,
HEWL or BSA (protein:TTR molar ratio was 10:1 unless otherwise stated;
protein:haptoglobin, protein:HEWL and protein:BSA molar ratio was 5:1;
protein:α2-macroglobulin was 100:1), and then added to the cells. Each
TTR (1.2 μM tetramer concentration) or 12 μM native HypF-N and Aβ42
were also used as controls. In additional experiments, 1 μM staurosporine
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in the absence or presence of each TTR and it was then added to the cells.
2.6. Measurement of intracellular Ca2+
Preformed HypF-N and Aβ42 oligomers (12 μM monomer con-
centration) were incubated for 60 min in the absence or presence
of hTTR, muTTR or M-TTR (TTR concentration as described above),
and then added to SH-SY5Y cells and rat hippocampal and cortical
neurons seeded on glass coverslips for 60 min at 37 °C. Cells were
also treated with 12 μMnative HypF-N and Aβ42 or each TTR at a tetra-
mer concentration of 1.2 μM. To detect intracellular Ca2+ cells were
then loaded with 10 μM ﬂuo3-AM (Life Technologies, CA, USA) as de-
scribed previously [35]. Cell ﬂuorescence was analyzed by confocal
Leica TCS SP5 scanning microscope (Mannheim, Germany) equipped
with an argon laser source for ﬂuorescence measurements at 488 nm
and a Leica Plan Apo 63 × oil immersion objective. A series of optical
sections (1024 × 1024 pixels) 1.0 μm in thickness was taken through
the cell depth for each examined sample. The confocal microscope
was set at optimal acquisition conditions, e.g., pinhole diameters, detec-
tor gain and laser powers. Settings were maintained constant for each
analysis.
2.7. Caspase-3 activity
Preformed HypF-N and Aβ42 oligomers (12 μM monomer concen-
tration) were incubated for 1 h in the absence or presence of each TTR
(TTR concentration as described above), and then they were added for
24 h to SH-SY5Y cells seeded on glass cover slips at 37 °C. Caspase-3 ac-
tivity was evaluated by loading cells with FAMFLICA™ Caspases 3 & 7
solution [Caspase 3 & 7 FLICA kit (FAM-DEVDFMK), Immunochemistry
Technologies, LLC, Bloomington, MN, USA], after treatment with oligo-
mers. Cells were also treated with 12 μM native HypF-N and Aβ42 or
each TTR at a tetramer concentration of 1.2 μM. The analysis of cell ﬂuo-
rescence and the microscope settings was described above.
2.8. Thioﬂavin T assay
Preformed HypF-N oligomers (12 μM monomer concentration)
were incubated for 1 h at 37 °Cwith shaking in the presence or absence
of each TTR (HypF-N:TTR molar ratio as described above). Aliquots of
these samples were added to a solution of 25 μM thioﬂavin T (ThT)
dissolved in 25 mM phosphate buffer at pH 6.0, in order to obtain a
3.7-fold molar excess of dye. Final protein concentration was 6 μM.
The steady-state intensity of ﬂuorescence emission at 485 nm (excita-
tion at 440 nm)was recorded at 37 °C. Each TTR (1.2 μM tetramer con-
centration) and 12 μM native HypF-N were also used as controls.
2.9. Pyrene ﬂuorescence emission spectra
HypF-N variants carrying a single cysteine residue were labeled with
N-(1-pyrene)maleimide and converted into toxic aggregates as previ-
ously reported [31] and then 4-fold diluted into 20 mMpotassium phos-
phate buffer at pH 7.0. Fluorescence emission spectra of these samples
were measured after 1 h of incubation at 37 °C under shaking in the ab-
sence and presence of each TTR. The spectra were acquired with 12 μM
HypF-N, at 37 °C, with an excitation of 344 nm using a Perkin-Elmer LS
55 spectroﬂuorimeter (Wellesley, MA) equipped with a thermostated
cell holder attached to a Haake F8 water bath (Karlsruhe, Germany),
and a 1.5 × 1.5 mm quartz cell. The spectra were normalized to the in-
tensity of the peak centered at 375 nm.
2.10. Intrinsic ﬂuorescence
HypF-N oligomers and each TTR incubated in isolation and in combi-
nation as described before were centrifuged for 10 min at 16,100 rcf.The intrinsic ﬂuorescence of the supernatants (SNs) were measured at
37 °C with excitation at 280 nm using a Perkin-Elmer LS 55 spectro-
ﬂuorimeter (Wellesley, MA) equipped with a thermostated cell
holder attached to a Haake F8 water bath (Karlsruhe, Germany),
and a 2 × 10 mm quartz cell. The spectrum of HypF-N oligomers
has been subtracted from that of TTR + HypF-N oligomers.
2.11. SDS-Page
HypF-N oligomers and each TTR incubated in isolation and in combi-
nation as described above were centrifuged for 10 min at 16,100 rcf.
Pellets and SN aliquotswere collected andmixedwith 4× sample buffer
with 20% 2-mercaptoethanol. Sodium dodecylsulfate polyacrylamide
gel electrophoresis (SDS-PAGE) analysis was performed in accordance
with Laemmli [36] using a 16% polyacrylamide gels. Proteins were visu-
alized by Coomassie Blue staining (0.1% Coomassie Blue, 10% acetic acid,
40% methanol). The densitometric analysis was obtained using ImageJ
software (NIH, Bethesda, MD, USA).
2.12. Atomic force microscopy
HypF-N/Aβ42 oligomers (12 μMmonomer concentration) were incu-
bated for 1 h at 37 °C under shaking in 20 mMpotassiumphosphate buff-
er at pH 7.0, in the presence or absence of each TTR. Sampleswere diluted
1000-fold and immediately deposited on a freshly cleavedmica substrate
and dried under a gentle nitrogenﬂux. Non-contact ACmode atomic force
microscopy (AFM) images were acquired in air using a PicoSPM micro-
scope equippedwith anAC-mode controller (Molecular Imaging, Phoenix,
AZ). Rectangular non-contact cantilever (modelNSG01,NT-MDTMoscow,
Russia), with typical resonance frequency of 150 kHz, were used.
Oligomer sizes were measured from the height in cross section of the
topographic AFM images.
2.13. Light scattering measurements
HypF-N oligomers (12 μM monomer concentration) were incubated
for 1 h at 37 °C under shaking in 20 mM potassium phosphate buffer at
pH 7.0 in the absence or presence of each TTR. Samples containing TTRs
were also used as controls and ﬁltered using 20 nm Anotop ﬁlters
(Sigma-Aldrich, Milan, Italy). The measurements were performed using
a Zetasizer Nano S DLS device from Malvern Instruments (Malvern,
Worcestershire, UK), thermostated with a Peltier system and using a
low-volume (45 μl), ultramicro cell (code 105.251-QS) fromHellma Ana-
lytics (Müllheim, Germany). Size distributions by intensity and total light-
scattering intensity were determined at regular time-intervals over a
period of 10 min. The temperature was maintained at 37 °C and the pa-
rameters were set manually on the instrument to allow the same settings
in the various distributions acquired at different time-values. These in-
cluded ten acquisitions each of 10 second duration, with cell position
4.2 cm and attenuator index 7. The reported data are the average of
three consecutive measurements.
2.14. Turbidimetry
HypF-N oligomers (12 μMmonomer concentration)were incubated
for 1 h at 37 °C under shaking in 20 mMpotassium phosphate buffer at
pH 7.0 in the absence or presence of each TTR. Samples containing TTRs
were also used as controls. Subsequently, the absorbance of the samples
at 500 nmwasmeasured using a Jasco V-630UV–Vis Spectrophotometer
(Tokyo, Japan) and a cell path of 0.1 cm. All the measurements were
blank-subtracted.
2.15. Confocal microscopy analysis for TTR-HypF-N oligomer binding
HypF-N oligomers (at a corresponding monomer concentration
of 48 μM) were incubated for different time lengths (0, 5, 15, 30
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to obtain pellet that were resuspended and incubated subsequently for
30 min at 37 °C in solutions containing: (i) 1:4000 rabbit polyclonal anti-
HypF-N antibodies (Primm) and mouse monoclonal anti-TTR antibodies
(Santa Cruz Biotechnology), (ii) 1:1000 Alexa Fluor 488-conjugated anti-
rabbit secondary antibodies (Life Technologies, CA, USA), and (iii) Alexa
Fluor 594-conjugated anti-mouse secondary antibodies (Life Technologies,
CA, USA). After every incubation, samples were centrifuged for 10 min at
16,100 ×g, washed in PBS, and centrifuged again. Finally, the pellet was re-
suspended in 20 μl PBS and spotted on glass coverslips. The cross-reactivity
of oligomers was tested by subsequent incubations with primary and sec-
ondary anti-TTR antibodies. Confocal microscope images were acquired as
described above.2.16. Statistical analysis
Datawas expressed asmean ± standard deviation (SD). Light scatter-
ing data was expressed as mean ± standard error of the mean (SEM).
Comparisons between different groups were performed using ANOVA
followed by Bonferroni's post-comparison test. A p-value lower than
0.05 was considered statistically signiﬁcant.Fig. 1. Suppression of protein oligomer toxicity by TTRs. Preformed oligomers of HypF-N (A) and
ingmonomer concentration of 12 μM in the absence or presence of the indicated TTRs (protein:T
humanα2-macroglobulin (protein:α2-macroglobulinmolar ratiowas 100:1), HEWL (protein:H
SY5Y cells. (C–D) Dose-dependent suppression of HypF-N (C) and Aβ42 (D) oligomer toxicity by
dium, incubated for 1 h in the absence (●) or presence of the indicated HypF-N:TTR/chaperone
always considered as tetramers in all HypF-N/Aβ42:TTR molar ratio values. The scale on the x a
with respect to untreated cells (taken as 100%). The values shown aremeans ± SD of three ind
indicate a signiﬁcant difference (p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, respectively) relative to the ex3. Results
3.1. TTRs prevent oligomer-induced cytotoxicity in SH-SY5Y cells
We incubated oligomers formed fromHypF-N andAβ42 in cell culture
medium in the absence or presence of hTTR, muTTR or M-TTR for 1 h,
then added the resulting mixtures to SH-SY5Y cells and measured the
resulting cell viability using the MTT reduction assay. The two types of
oligomers were toxic (Fig. 1A, B), as previously demonstrated [26]. The
cells treated with oligomers preincubated with hTTR and M-TTR dis-
played no toxic effect showingMTT reduction similar to that of untreated
cells, to cells treatedwith the native proteins or to cells treatedwith olig-
omers preincubated with haptoglobin or α2-macroglobulin, two well
known extracellular chaperones used here as positive controls for inhibi-
tion of oligomer toxicity (Fig. 1A, B). Conversely,muTTR shows a small in-
signiﬁcant protective effect (Fig. 1A, B). In addition, when the two
oligomer types were incubated in the cell culture medium for 1 h with
proteins that are not expected to possess chaperone properties, such as
hen egg white lysozyme (HEWL) or bovine serum albumin (BSA), the
oligomers maintained their toxicity (Fig. 1A, B). In these studies we did
not examine the effect of the various TTRs on Aβ42 and HypF-N oligomer
formation.Aβ42 (B)were resuspended in the cell culturemedium, incubated for 1 h at a correspond-
TRmolar ratiowas 10:1), humanhaptoglobin (protein:haptoglobinmolar ratiowas 15:1),
EWLmolar ratiowas 5:1), or BSA (protein:BSAmolar ratiowas 5:1) and then added to SH-
TTRs. Preformed oligomers of HypF-N and Aβ42 were resuspended in the cell culture me-
(C) and Aβ42:TTR/chaperone (D)molar ratios and then added to SH-SY5Y cells. TTRs were
xis is logarithmic. Cell viability was expressed as percent of MTT reduction in treated cells
ependent experiments carried out in quadruplicate. The single, double and triple asterisks
periment with oligomers only.
2306 R. Cascella et al. / Biochimica et Biophysica Acta 1832 (2013) 2302–2314We repeated the experiments described above for HypF-N and Aβ42
oligomers by varying the concentration of each TTR in the 1 h pre-
incubation solution, while maintaining a constant concentration of
HypF-N and Aβ42. M-TTR was found to suppress the toxicity of HypF-N
and Aβ42 oligomers even at low concentration with an efﬁcacy similar
to haptoglobin and α2-macroglobulin (Fig. 1C, D). M-TTR remained ef-
fective even at an HypF-N:TTR and Aβ42:TTR molar ratio of 400:1, be-
coming ineffective at a molar ratio of 1000:1 both for HypF-N and Aβ42
(Fig. 1C, D). hTTR is also effective, but at higher concentrations; indeed,
hTTR inhibited toxicity until a HypF-N:TTR and Aβ42:TTR molar ratio of
40:1 and 100:1, respectively, only becoming ineffective at molar ratios
of 100:1 forHypF-N and 200:1 for Aβ42.muTTRdid not show anyprotec-
tive effect, even at low molar ratios (Fig. 1C, D).
We also evaluated the intrinsic cytotoxic effect of each TTR variant in
the absence of the oligomers. Our results showed that under our exper-
imental condition (preincubation for 1 h at 37 °C) M-TTR signiﬁcantly
decreased the MTT reduction of the SH-SY5Y cells by ca. 20% (Suppl.
Fig. 1A); conversely, hTTR andmuTTR did not show signiﬁcant toxic ef-
fects (Suppl. Fig. 1A), whereas it has been demonstrated that hTTR is cy-
totoxic if produced or exposed to cold temperature [37,38]. These
results indicate that M-TTR alone is toxic to cells, as previously demon-
strated [39], whereas preincubation of M-TTR with toxic HypF-N and
Aβ42 oligomers suppresses both toxic effects, suggesting an interaction
between oligomers and monomeric TTR with mutual suppression of
toxicity.
To assess whether the three types of TTR can protect the cells from
other forms of stress, or if they are speciﬁc for protein oligomers, we in-
cubated the cells with staurosporine, a well-known apoptosis inducer.
We found that a concentration of 1 μM of staurosporine decreased the
MTT reduction of the cells to a level similar to that of preformed protein
oligomers under our conditions. The staurosporine toxicity was not re-
duced by any of the three TTRs (Suppl. Fig. 1B).
These results indicate that hTTR andM-TTR can suppress ormarkedly
decrease the toxicity of oligomers formed by two different peptides and
proteins. The suppression is speciﬁc for TTRs or chaperones (relative to
other proteins) with respect to toxicity induced by preformed protein
oligomers (not other forms of stress).3.2. TTRs inhibit oligomer-mediated intracellular Ca2+ inﬂux, ROS
production and membrane permeabilization
The inﬂux of Ca2+ ions from the extracellular space into the cytosol
across the cell membrane has been recognized to be an early biochem-
ical change undergone by cells exposed to deleterious protein oligo-
mers including HypF-N and Aβ42 oligomers [35,40–44]. Here we
compared the ability of the different types of TTR to inhibit the inﬂux
of Ca2+ caused by soluble oligomers of HypF-N and Aβ42 after their
preincubation for 1 h in the cell culture medium before addition to
the SH-SY5Y cells. Both HypF-N and Aβ42 oligomers induced a sharp in-
crease in cytosolic free Ca2+ levels (Fig. 2). Preincubationwith hTTRand
M-TTR was found to inhibit the increase of intracellular Ca2+ levels
caused by the oligomers, whereas muTTR showed a lower protective
effect (Fig. 2). In addition, the degree of Ca2+-derived ﬂuorescence
was found to decrease exponentially with the time of preincubation
with M-TTR and hTTR (Suppl. Fig. 2); in particular, M-TTR prevented
the Ca2+ spike after only 15 min of preincubation (Suppl. Fig. 2).
Similar results were obtained from analyzing intracellular ROS pro-
duction and membrane permeability. HypF-N oligomers induced a
sharp increase in ROS levels in our cell model (Suppl. Fig. 3A). hTTR
and M-TTR inhibited the increase of intracellular ROS levels caused by
the oligomers, with the degree of ROS-derived ﬂuorescence decreasing
exponentially with the time of preincubation (Suppl. Fig. 3A); M-TTR
prevented the ROS production after only 15 min of preincubation
(Suppl. Fig. 3A). In contrast, mTTR did not show any protective effect
(Suppl. Fig. 3A).Confocal microscopy analysis of SH-SY5Y cells pre-loaded with
calcein-AM showed that cell exposure to HypF-N toxic oligomers
resulted in a signiﬁcant decrease of ﬂuorescence intensity in our cells,
indicating increased membrane permeabilization (Suppl. Fig. 3B). In
contrast, the reduction in calcein ﬂuorescence was prevented when
the cells were treated with oligomers preincubated with hTTR and
M-TTR, with the degree of calcein-derived ﬂuorescence increasing
exponentially with the time of preincubation (Suppl. Fig. 3B). In par-
ticular, the reduction of permeabilization occurred even more quickly
in the presence of M-TTR. mTTR did not show any protective effect
(Suppl. Fig. 3B).
3.3. TTRs prevent oligomer-induced apoptosis
We then evaluated whether the different capacities of TTRs to pro-
tect cytosolic Ca2+ inﬂux, ROS production and membrane perme-
abilization induced by HypF-N and Aβ42 oligomers also resulted in
different abilities to prevent cell death.Wemeasured Caspase-3 activity,
a well recognized apoptotic marker, using confocal microscopy (Fig. 3)
[45]. Fluorescence microscopy images and the corresponding semi-
quantitative values of the green ﬂuorescence signal show that hTTR
and M-TTR signiﬁcantly prevented the apoptotic response induced by
HypF-N and Aβ42 oligomers (Fig. 3A, B; p b 0.01). muTTR also showed
a signiﬁcant protection but it was less marked than that of the other
TTRs (Fig. 3A, B; p b 0.05). A similar trend was observed in analyzing
chromatin condensation by using the Hoechst 33342 dye, a ﬂuorescent
marker that binds to the highly condensed chromatin present in the nu-
clei of apoptotic cells [46] (Suppl. Fig. 4).
3.4. TTRs prevent oligomer-induced toxicity and inhibit colocalization
of HypF-N aggregates with PSD-95 in rat primary neurons
We assessed the relative protective capacity of the three different
TTRs for rat hippocampal and cortical neurons using the MTT reduction
assay. The HypF-N oligomers were toxic to rat hippocampal and cortical
neurons (Suppl. Fig. 5A,B). The neurons treated with HypF-N oligomers
pre-incubated with hTTR and M-TTR were found to reduce MTT to
levels similar to untreated cells and to cells treated with the native
protein (Suppl. Fig. 5A, B); conversely, muTTR showed a small and
non-signiﬁcant protective effect (Suppl. Fig. 5A, B). We also evaluated
the intrinsic cytotoxic effect of each TTR variant in the absence of the
oligomers. M-TTR signiﬁcantly decreased theMTT reduction of neurons
by 25% (Suppl. Fig. 5A, B); conversely hTTR and muTTR did not show
any signiﬁcant toxic effect (Suppl. Fig. 5A, B). These results indicate
that as previously shown for Aβ induced cytotoxity, hTTR and M-TTR
are able to suppress HypF-N oligomer-induced toxic effects in both im-
mortalized cell cultures and primary neurons.
To investigate the mechanism of action by which TTRs protect cul-
tured primary neurons from toxic HypF-N oligomers, we examined
the colocalization between oligomers and PSD-95 in cultured primary
hippocampal neurons. It has previously been shown that binding sites
of Aβ42 and HypF-N oligomers on neurons overlap with PSD-95
[47–49]. A remarkable degree of colocalization was observed between
HypF-N oligomers and PSD-95, whereas no colocalizationwas observed
in untreated cells or in cells treatedwith native HypF-N (Suppl. Fig. 5C).
Preincubation of HypF-N oligomers with hTTR or M-TTR for 1 h was
found to inhibit oligomer binding to the cell membrane, thus pre-
venting the colocalization with PSD-95 (Suppl. Fig. 5C). Preincubation
of HypF-N oligomers with muTTR also decreased colocalization, but to
a lower level than observed for the other TTRs (Suppl. Fig. 5C). In
particular, the fraction of HypF-N puncta colocalizing with PSD-95
puncta was 21.4 ± 3.1% (n = 18) for oligomers preincubated with
hTTR for 1 h, 35.7 ± 1.2% (n = 18) for oligomers preincubated with
muTTR for 1 h and 16.5 ± 1.2% (n = 18) for oligomers preincubated
with M-TTR for 1 h.
Fig. 2. Representative confocal scanningmicroscope images showing intracellular Ca2+ levels in SH-SY5Y cells. Preformed oligomers of HypF-N (A) and Aβ42 (B) were resuspended in the
cell culturemedium, incubated for 1 h at a correspondingmonomer concentration of 12 μMwith or without the indicated TTRs (protein:TTRmolar ratiowas 10:1) and then added to SH-
SY5Y cells for 1 h. The ﬁgure also shows untreated cells, cells exposed for 1 h to the native protein, to toxic oligomers (12 μMmonomer) and to the indicated TTRs alone (1.2 μM tetramer
or 4.8 μMmonomer). The green ﬂuorescence arises from the intracellular Fluo3 probe bound to Ca2+. The corresponding semi-quantitative values of the green ﬂuorescence signals are
shown below each set of images. Statistics as in Fig. 1.
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intracellular Ca2+ increase in both hippocampal (Suppl. Fig. 6A) and
cortical neurons (Suppl. Fig. 6B). They also inhibited intracellular ROS
production in hippocampal neurons (Suppl. Fig. 6C). These results
show that preincubation of the HypF-N oligomers with hTTR and
M-TTR, and to a lesser extentmuTTR, inhibit the binding of the oligomers
at PSD-95 containing sites and reduce the toxicity of the oligomers for
neurons.
3.5. The molecular structure of HypF-N oligomers is preserved in the
complexes with TTRs
In order to investigate the mechanism by which TTRs suppress the
toxicity of protein oligomers, we have chosen to focus on the toxic olig-
omers of HypF-N. Indeed, under different experimental conditions,HypF-N can aggregate into toxic (type A, the same used in the present
work) or nontoxic (type B) oligomers; using atomic force microscopy
(AFM) the two species are morphologically similar (ca. 2–6 nm in
height) and bind ThT to similar levels, making it possible to carry out
valuable control experiments [30]. Thus, HypF-N oligomers appear to be
highly stable, making them easy to handle in our experiments [30]. We
have, however, carried out the key experiments also on Aβ42 oligomers
(see below).
To shed light on the behaviors of the various TTRs and on themolec-
ular mechanism by which they exert their protection against HypF-N
oligomerswe investigated the oligomeric state and themolecular struc-
ture of HypF-N oligomers after preincubation with various TTRs. To as-
sess whether the oligomers can be dissolved by the different types of
TTR, we exploited the ability of the HypF-N oligomers, unlike native
HypF-N, to bind to ThT and increase its ﬂuorescence [30] (Fig. 4A).
Fig. 3. Representative confocal microscope images showing Caspase-3 activation in SH-SY5Y cells. Preformed oligomers of HypF-N (A) and Aβ42 (B) were resuspended in the cell culture
medium, incubated at a corresponding monomer concentration of 12 μMwith or without the indicated TTRs (protein:TTRmolar ratio was 10:1) for 1 h and then added to SH-SY5Y cells
for 24 h. Theﬁgure also shows untreated cells, cells exposed for 1 h to the native protein, to toxic oligomers (12 μMmonomer) and to the indicated TTRs alone (1.2 μMtetramer or 4.8 μM
monomer). Caspase-3 activity, assessed using the ﬂuorescent probe FAM-FLICA™ Caspases 3 & 7, is indicated by green ﬂuorescence. The corresponding semi-quantitative values of the
green ﬂuorescence signals are shown below each set of images. Statistics as in Fig. 1.
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cause a seven to eight fold increase of ThT ﬂuorescence, and the same
increase was observed when the oligomers were preincubated in the
same buffer for 1 h with each of the TTRs (Fig. 4A). To exclude the pos-
sibility that TTRs bind ThT, in parallel we also analyzed samples contain-
ing only TTRs under identical conditions and detected no increase of ThT
ﬂuorescence in these cases (Fig. 4A). Overall, these results show that
HypF-N oligomers remain stable and do not undergo disaggregation
after TTR treatment.
Subsequently, we asked whether the oligomers are structurally re-
organized at the molecular level by the TTRs (Fig. 4B). Differences in
the structure of toxic and non-toxic oligomers have been detected
using the ﬂuorescent probe pyrene, a structural probe for changes in
oligomers exposed to chaperones [30]. We determined the degree of
packing of the oligomers through the acquisition ofﬂuorescence spectra
of oligomers labeled with pyrene. This method consists in creatingHypF-N variants containing a single cysteine at different positions
along the sequence, label them with pyrene and allow the labeled mu-
tants to aggregate. When two pyrene molecules are close to each
other (within 10 Å of distance), excited state dimers called excimers
form and can be detected as a peak at 440–470 nm [50–52]. It has
been shown that toxic and non-toxic HypF-N oligomers can be distin-
guished by differences in their pyrene emission spectra [30].
Three variants of HypF-N containing a single cysteine residue at posi-
tion 25, 55 or 87, all located in the major hydrophobic regions, were la-
beled with pyrene, allowed to aggregate and were transferred to
phosphate buffer at neutral pH for 1 h with or without the different
forms of TTR. The ﬂuorescence spectra acquired for the oligomers in
either the presence or absence of the TTRs were very similar with none
showing an excimer band (Fig. 4B). Moreover, the ratio of the excimer-
to-monomer ﬂuorescence intensity (FI440nm/FI375nm) did not change fol-
lowing preincubationwith any TTR, remaining lower in all cases than the
Fig. 4. TTRs do not dissolve and do not remodel HypF-N oligomers. (A) ThT ﬂuorescence at 485 nm (excitation 440 nm) in the presence of the indicated protein components following
preincubation for 1 h in 20 mM phosphate buffer at pH 7.0 in the absence or presence of different types of TTR. The ratio between the ThT ﬂuorescence in the presence (F) and absence
(F0) of proteins is reported; data aremeans ± SDof three independent experiments. The HypF-N concentrationwas 48 μM(inmonomer units) and theHypF-N:TTRmolar ratiowas 10:1.
(B) Fluorescence emission spectra of samples containing HypF-N oligomers labeled with pyrene at positions 25 (top), 55 (middle) and 87 (bottom). The spectra were acquired at 12 μM
HypF-N concentration following 1 h incubation in the absence (green) or presence (pink) of hTTR (left panels), muTTR (middle panels) or M-TTR (right panels). For comparison, the cor-
responding spectra of nontoxic oligomers are reported in each graph (black). The spectra have beennormalized to the intensity of the peak centered at 375 nm. Themolar ratio of HypF-N:
TTR was 10:1. On the right, the excimer-to-monomer ﬂuorescence intensity (FI440nm/FI375nm) of each sample and of the nontoxic oligomers [30] is reported.
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results show that none of the TTRs promote structural re-organization of
the toxic HypF-N oligomers.
3.6. TTRs bind to the oligomers
To determine whether TTRs bind to the oligomers we used TTR-
derived intrinsic ﬂuorescence and SDS-PAGE. HypF-N oligomers sedi-
ment at relatively low centrifugal force; therefore, if the TTRs bind tothe oligomers and the interaction between them is stable, the concentra-
tion of the TTRs in the supernatantwill decrease following centrifugation,
depending on the strength of the interaction. HypF-N oligomers and TTRs
were incubated for 1 h in phosphate buffer at pH 7.0 then centrifuged to
separate the pellet fraction (P), which contains the TTR bound to the olig-
omers, from the supernatant (SN), which contains the soluble unbound
TTR. The amount of TTR in the SN was measured by its intrinsic ﬂuores-
cence (Fig. 5A–C). The ﬂuorescence spectra of the SNs collected from
the samples in which oligomers and hTTR or M-TTR were present were
Fig. 5. TTRs interact with HypF-N oligomers. (A–C) Intrinsic ﬂuorescence spectra of the SN fractions obtained after centrifugation of samples containing preformed HypF-N oligomers
(blue), TTR (red) and HypF-N oligomers + TTR (purple). The ﬂuorescence emission spectra (excitation at 280 nm) were acquired at 37 °C. The spectrum of HypF-N oligomers has
been subtracted from that of TTR + HypF-N oligomers to eliminate its contribution. (D–F) SDS-PAGE analysis of the insoluble (P) and soluble (SN) fractions obtained from samples con-
taining preformedHypF-N oligomers (lanes 2, 3), TTR (lanes 4, 5) andpreformed oligomers treated for 1 hwith TTR (lanes 6, 7). TheHypF-N concentrationwas 48 μM(inmonomer units)
and the molar ratio of HypF-N:TTR was 10:1.
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present, indicating that a fraction of hTTR, and to a greater extent M-
TTR, is bound to the oligomers. In contrast, the ﬂuorescence spectrum
of the SN collected from the sample containing oligomers and muTTR
was similar to that in which only muTTR was present.
As a further evidence of binding, the pellet and supernatant fractions
collected in each experiment were analyzed by SDS-PAGE. In the sam-
ples containing oligomers or TTR alone, the HypF-N monomer (MW
~10.5 kDa) and the TTR monomer (MW ~14 kDa) were found only in
the pellet and SN fractions, respectively (Fig. 5D–F). In the sample
containing both HypF-N oligomers and M-TTR, the HypF-N band was
present only in the pellet fraction, whereas M-TTR was found to parti-
tion between the pellet (49.8% ± 2.6) and SN fractions (Fig. 5F). This re-
sult conﬁrms that a fraction of M-TTR is bound to the oligomers. Similar
results, but with evidence of a smaller fraction bound in the pellet
(24.1% ± 3.1), were obtained with hTTR (Fig. 5D). In contrast, we
found muTTR only in the SN fraction, suggesting that muTTR did not
bind to HypF-N oligomers under these conditions (Fig. 5E). These re-
sults suggest that the ability of TTRs to bind HypF-N oligomers corre-
lates inversely with TTR tetramer stability.
3.7. TTRs promote the assembly of the oligomers into larger species
To investigate whether the binding of TTRs to the oligomers pro-
motes their further assembly, we ﬁrst used AFM. Discrete HypF-N olig-
omers with a height of 1–4 nmwere observed by AFM in the absence of
TTR (Fig. 6A), but signiﬁcantly larger aggregates were evident after 1 h
incubation in the presence of M-TTR and, to a lower extent, hTTR
(Fig. 6A). More complex structures were observed in the presence of
M-TTR, consisting of very large aggregates of irregular shape with typi-
cal heights of a few tens of nanometers. Large assemblies were notobserved in samples containing oligomers with muTTR (Fig. 6A), or in
samples containing only TTR. Similar results were obtained with Aβ42
oligomers and TTRs (Suppl. Fig. 7A).
As additional evidence of the ability of TTRs to promote oligomer as-
sembly, we took advantage of light scattering measurements. In the
presence ofM-TTR, and hTTR to a lower extent, light scattering intensity
increased, indicating that the oligomers were larger in size (Fig. 6B). Ac-
cordingly, these results were conﬁrmed with turbidimetry measure-
ments at 500 nm, which revealed a similar trend, presumably related
to the lower sensitivity of this method (Fig. 6C).
The AFM, light scattering and turbidity results show that M-TTR and
hTTR promote the assembly of the HypF-N oligomers into larger species
but do not provide information on whether or not the large HypF-N ag-
gregates include the TTRs. The oligomers can also be observedwith con-
focal microscopy because, unlike free TTRs, they readily adhere to the
glass coverslips (Fig. 7). Images obtained using HypF-N oligomers incu-
bated for 1 h with TTRs show larger aggregates, with M-TTR and hTTR
colocalizingwith the large oligomer clusters (Fig. 7). By contrast, images
obtained using HypF-N oligomers and TTRs in the absence of 1 h incu-
bation showed no large oligomers (Fig. 7). Indeed, incubation of HypF-
N oligomers with M-TTR promoted formation of large aggregates in a
time-dependent manner (Fig. 7, bottom panel). Interestingly, the TTRs
appear within the structural core rather than on the surface of these
larger aggregates, suggesting that they promote the formation of such
large aggregates rather than binding and stabilizing them after they
are formed (Fig. 7). On the other hand, mTTR did not colocalize with
the oligomers. This technique also showed that the M-TTR and hTTR
were bound only to the large clusters of oligomers, not to single oligo-
mers, conﬁrming that the binding promotes their further assembly
into clusters. Similar results were obtained with Aβ42 oligomers and
M-TTR (Suppl. Fig. 7B).
Fig. 6. Assembly of HypF-N oligomers induced by TTRs. (A) AFM images and corresponding height analysis of HypF-N oligomers preincubatedwith or without TTRs. Preformed oligomers
of HypF-Nwere resuspended in phosphate buffer pH 7.0, incubated for 1 h at a correspondingmonomer concentration of 48 μM in the absence or presence of the indicated TTRs (HypF-N:
TTR molar ratio was 10:1) and then deposited on mica; the scan size is 1 μm. Z range: 5 nm (oligomers), 24 nm (oligomers + hTTR), 6 nm (oligomers + muTTR), 36 nm
(oligomers + M-TTR). (B) Light scattering intensitymeasurements of HypF-Noligomers preincubatedwith orwithout TTRs and TTRs alone. The light scattering intensitiesweremeasured
at 48 μMHypF-N andat aHypF-N:TTRmolar ratio of 10:1. (C)Measurements of turbidimetry at 500 nmofHypF-Noligomers incubatedwith orwithout TTRs andTTRs alone. Conditions as
in (B). The values shown are means ± SEM of ﬁve independent experiments. The single and the triple asterisks indicate signiﬁcant difference (p ≤ 0.05 and p ≤ 0.001, respectively) rel-
ative to the experiment with oligomers only.
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TTRwas shown to inhibit aggregation and amyloid plaque formation
of Aβ both in vitro and in vivo [17–21, 23, Li et al., submitted]. Analyses
carried out in vitro have shown that TTR binds monomeric Aβ,
explaining its ability to prevent aggregation of the peptide [22, 23, Li
et al., in preparation]. However, in experiments using various forms of
Aβ ﬁxed to solid surfaces (e.g., nitrocellulose membranes or Biacore
chips) TTR-Aβ bindingwas found to occurwith higher afﬁnity for aggre-
gated Aβ, such as oligomers and ﬁbrils, relative to monomeric Aβ, with
monomeric TTR exhibiting stronger binding than tetrameric TTR [20, 21,
23, Li et al., submitted]. The high afﬁnity between monomeric TTR and
aggregated Aβ suggests an important role for such an interaction
in vitro. Indeed, TTR was shown to bind to preformed Aβ oligomers
and reduce their toxicity tomurine primary neurons and human neuro-
blastoma SH-SY5Y cells [25]. In those studies, the suppression of TTR-
mediated toxicity was not due to the ability of TTR to inhibit Aβ aggre-
gation, but appeared to act on preformed oligomers. Subsequent studies
have shown that hTTR both inhibits Aβ oligomer formation and inter-
acts with small Aβ oligomers to prevent the formation of nucleation
competent seeds [Li et al., submitted].
Here, we found that TTR is able to suppress the toxicity of extracel-
lularly added oligomers formed by two different peptides/proteins,
namely Aβ42 and HypF-N, adding new data to the preliminary observa-
tion obtainedwith Aβ42 [25]. TTRwas found to inhibit the inﬂux of Ca2+caused by the oligomers, thus eliminating the occurrence of later effects,
manifested as oxidative stress, membrane leakage and apoptosis. In
addition, the observed dependence of the degree of protection on the
time of preincubation between oligomers and TTR indicates that TTR
suppresses oligomer toxicity by interacting with the oligomers, rather
than through a separate protective pathwaymediated by direct interac-
tion of TTR with the cells. Overall, therefore, these ﬁndings reveal that
the deleterious effects produced by interaction of misfolded protein
oligomers with cell membranes can be abolished by TTR.
The three types of TTR examined here, namely hTTR, muTTR and
M-TTR, were found to display different protective effects against
oligomer-induced cytotoxicity. Indeed, monomeric M-TTR was able
to protect SH-SY5Y neuroblastoma cells and rat primary neurons
against oligomer-induced cytotoxicity; the highly stable tetrameric
muTTR only showed only a small non-signiﬁcant protective effect,
whereas the less stable tetrameric hTTR had an effect intermediate
between the two forms, or displayed a protective action more slowly
or at higher concentrations than M-TTR. Hence, the ability of TTR to
protect neuronal cells and neurons against these misfolded protein
oligomers in vitro correlates inversely with the stability of the
tetramer.
To shed light on the molecular mechanism by which TTR prevents
cytotoxicity, we focused on HypF-N oligomers, probing their oligomeric
state and molecular structure after the incubation with TTRs in vitro.
Using ThT ﬂuorescence we found that TTR does not disaggregate the
Fig. 7. Colocalization of HypF-N oligomers and TTRs. Representative confocal microscope images with HypF-N oligomers incubated for the indicated time lengths in the absence or pres-
ence of the indicated TTRs and treatedwith anti-HypF-N (green) and anti-TTR (red) antibodies. The colocalization of oligomers and TTRs is shown in themerged images (yellow dots). The
HypF-N concentration was 48 μM (in monomer units) and the molar ratio of HypF-N:TTR was 10:1.
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organization of the discrete oligomers, as shown by site-directed pyrene
labeling. Rather, TTR was found to bind to the oligomers, as determined
with SDS-PAGE, intrinsic ﬂuorescence and confocal scanning microsco-
py, and promote their further assembly into larger aggregates, as shown
by AFM, light scattering measurements and turbidimetry. The ability of
TTR to bind to the oligomers and cause their clustering was also found
for Aβ42 oligomers, usingAFM and confocal scanningmicroscopy. Clear-
ly, the ability of TTR to bind to and further assemble preformed HypF-N
and Aβ42 oligomers correlated again inversely with its stability, as the
efﬁciency of such process followed the same order as that found for tox-
icity suppression, i.e., M-TTR N hTTR N mTTR. These data also suggest
that the size of extracellular protein aggregates is an inverse correlate
of their toxicity. The TTR-induced oligomer clusters are characterized
by a reduction in their exposed hydrophobic surface and diffusionalmo-
bility, both of which are expected to reduce their toxicity to cells
[26,53–56].
Recent structural analyses of the TTR/Aβ interaction have revealed a
complex set of interactions with hTTR tetramers binding the Aβmono-
mer in the T4 binding pocket to inhibit Aβ aggregation and cytotoxicity
[Li et al., submitted]. By contrast, M-TTRwas found to interact preferen-
tially with Aβ oligomers [Li et al., submitted], and this observation is
consistent with the better binding of M-TTR to HypF-N oligomers
shown here. Nevertheless, the M-TTR/Aβ oligomer interaction was not
found to be associated with a size increase of the oligomers [Li et al.,
submitted], whereas in our experimental conditions the interaction be-
tweenM-TTR and HypF-N/Aβ42 oligomers was found to involve further
clustering of the oligomers. The interaction showed by Li et al. was ob-
tained under different conditions compared to those used in the present
study.M-TTRwas added to the aggregation assaywhere Aβwas initially
monomeric [Li et al., submitted]. Here we added M-TTR to pre-formed
HypF-N/Aβ42 oligomers. Such a difference parallels the data showed
by Ojha et al. showing that the chaperone HspB1 converted the pre-
formed oligomers of Aβ into large aggregates, whereas, the incubation
with Aβmonomer did not produce such larger species [53]. Hence, it ap-
pears that in vitro the different experimental conditions, i.e., the use of
monomeric aggregating protein with respect to oligomeric species,
may determine a different mode of M-TTR/oligomer interaction and
suppression of oligomer toxicity. Further experimental studies are nec-
essary to clarify this issue.
Overall, themolecularmechanismbywhich TTR protects cells against
the deleterious effects of protein aggregation seems to involve two differ-
ent levels of intervention, inhibition of protein aggregation and ﬁbril for-
mation, as previously demonstrated [17–21, 23, Li et al., submitted], and
neutralization of protein oligomer toxicity once the oligomers are formed,
as shown here. Such dual protective behavior has also been demonstrat-
ed in vitro for a number of proteins that have been widely recognized as
molecular chaperones, such asαB-crystallin, Hsp70 (bothwith andwith-
out ATP), clusterin, α2-macroglobulin and haptoglobin [26,57], showing
that TTR can also behave as amoleculewith ATP-independent chaperone
activity and have a relevant functional role in vivo.Conﬂict of interest
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